このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

LLM-Generated Medical Summaries During Hospitalization to Improve Patient Activation in High-Risk Pregnancies

2026年9月12日 更新者:Avihu Krieger、Sheba Medical Center

The Effect of Large Language Model-Generated Medical Summaries on Patient Activation During Antepartum Hospitalization: A Randomized Controlled Trial

The goal of this clinical trial is to learn if AI-generated medical summaries help hospitalized pregnant participants better understand and actively participate in their own care. The main questions it aims to answer are:

Do AI-generated summaries increase participant activation (knowledge, skills, and confidence in managing their health)? How accurate are the AI-generated summaries, as assessed by physicians? Do AI-generated summaries affect depressive symptoms during hospitalization?

Researchers will compare participants who receive periodic AI-generated summaries of their medical care with participants who receive standard care to determine whether the summaries improve patient activation during hospitalization.

Participants will:

Be randomly assigned to receive AI-generated medical summaries or standard care.

Complete the Patient Activation Measure (PAM-13) at baseline before the intervention and again after the intervention.

Complete the Edinburgh Postnatal Depression Scale (EPDS) at baseline and again after the intervention.

Receive up to 3 summaries during their hospitalization (intervention group only).

調査の概要

詳細な説明

Hospitalized pregnant participants in high-risk antepartum units may face complex medical conditions and treatment plans and may have difficulty understanding all of the medical information provided during hospitalization. This may reduce their ability to actively participate in their own care.

In this study, participants will be randomly assigned in a 1:1 ratio to one of two groups. Randomization will be stratified by gestational age at enrollment (<32+0 weeks vs. ≥32+0 weeks) using permuted blocks with randomly varying block sizes.

Participants in the intervention group will receive periodic medical summaries generated by a large language model (LLM) using a secure, privacy-protected AI environment at Sheba Medical Center. Each summary will be reviewed by a physician for medical accuracy before being provided to the participant. If a summary is considered inadequate, the physician may correct it before providing it to the participant or reject it, in which case it will not be provided.

The first summary will be generated on days 3-5 of hospitalization. Updated summaries will subsequently be generated every 3-5 days, with a maximum of 3 summaries per participant during hospitalization.

Participants in the control group will receive standard care without LLM-generated medical summaries.

The researchers will investigate:

Whether LLM-generated summaries improve patient activation, defined as the knowledge, skills, and confidence participants have in managing their own health, as measured by the Patient Activation Measure (PAM-13).

Whether LLM-generated summaries affect depressive symptoms during hospitalization, as measured by the Edinburgh Postnatal Depression Scale (EPDS).

The accuracy of LLM-generated medical summaries as assessed by physicians, including whether summaries require modification or rejection before being provided to participants.

Obstetric, neonatal, and postpartum clinical outcomes collected from the medical record.

研究の種類

介入

入学 (推定)

200

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Avihu Krieger, MD
  • 電話番号:+972547421909
  • メール:avihuey@gmail.com

研究連絡先のバックアップ

研究場所

      • Ramat Gan、イスラエル、5262000
        • Sheba medical center
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Avihu Krieger, MD
        • 副調査官:
          • Abraham Tsur, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Admitted to the antepartum high-risk department at Sheba Medical Center
  • Able to provide written informed consent
  • Able to read and understand Hebrew, English, or Arabic

Exclusion Criteria:

  • Expected hospitalization of less than 3 days

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:LLM-Generated Medical Summaries
Participants receive periodic patient-facing written medical summaries generated by a large language model (LLM) using a secure, privacy-protected AI environment at Sheba Medical Center. This is an informational intervention and does not involve a drug, medical device, or medical procedure. Each summary is reviewed by a physician for medical accuracy before delivery. Summaries are generated every 3-5 days, beginning on days 3-5 of hospitalization, with a maximum of 3 summaries per participant.
Participants receive patient-facing written medical summaries generated by a large language model (LLM) using a secure, privacy-protected AI environment at Sheba Medical Center. The intervention is informational and does not involve administration of a drug, use of a medical device, or performance of a medical procedure. Each summary is reviewed by a physician for medical accuracy before being provided to the participant. If a summary is deemed inadequate, it may be corrected by the reviewing physician before delivery or rejected and not provided. The first summary is generated on days 3-5 of hospitalization, with updated summaries every 3-5 days and a maximum of 3 summaries per participant.
介入なし:Standard Care
Participants receive standard care, which does not include LLM-generated medical summaries.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Patient Activation Measure Score
時間枠:From baseline (pre-intervention) to post-intervention during hospitalization, approximately 1-8 weeks.
Change in Patient Activation Measure (PAM-13) score from baseline (pre-intervention) to post-intervention, compared between the intervention and control groups. The PAM-13 is a 13-item instrument assessing patient knowledge, skills, and confidence in managing their own health. Scores range from 0 to 100, with higher scores indicating greater patient activation.
From baseline (pre-intervention) to post-intervention during hospitalization, approximately 1-8 weeks.
Number of LLM-Generated Medical Summaries Requiring Physician Modification or Rejection
時間枠:Throughout hospitalization, approximately 1-8 weeks
Number of LLM-generated medical summaries that require physician modification or are rejected following physician review and prior to delivery to the participant.
Throughout hospitalization, approximately 1-8 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Edinburgh Postnatal Depression Scale Score
時間枠:From admission to discharge, approximately 1-8 weeks
Change in EPDS score from baseline (admission) to end of hospitalization (prior to discharge), compared between the intervention and control groups. The EPDS is a 10-item self-report instrument with scores ranging from 0 to 30. A score of 10 or above indicates clinically significant depressive symptoms.
From admission to discharge, approximately 1-8 weeks
Gestational Age at Delivery
時間枠:At delivery, up to approximately 6 months after enrollment.
Gestational age at delivery, measured in weeks and days, collected from the medical record and compared between the intervention and control groups.
At delivery, up to approximately 6 months after enrollment.
Mode of Delivery
時間枠:At delivery, up to approximately 6 months after enrollment.
Mode of delivery, categorized as spontaneous vaginal delivery, operative vaginal delivery, or cesarean delivery, collected from the medical record and compared between the intervention and control groups.
At delivery, up to approximately 6 months after enrollment.
Indication for Cesarean Delivery
時間枠:At delivery, up to approximately 6 months after enrollment.
Indication for cesarean delivery among participants undergoing cesarean delivery, collected from the medical record.
At delivery, up to approximately 6 months after enrollment.
Maternal Fever or Chorioamnionitis
時間枠:From enrollment through delivery, up to approximately 6 months.
Proportion of participants diagnosed with maternal fever or chorioamnionitis during pregnancy or delivery, collected from the medical record and compared between the intervention and control groups.
From enrollment through delivery, up to approximately 6 months.
Length of Antepartum Hospitalization
時間枠:From admission to discharge from the antepartum hospitalization, approximately 1-8 weeks.
Duration of antepartum hospitalization in days, collected from the medical record and compared between the intervention and control groups.
From admission to discharge from the antepartum hospitalization, approximately 1-8 weeks.
Antepartum Readmission or Emergency Department Visit
時間枠:From discharge from the index hospitalization through delivery, up to approximately 6 months after enrollment.
Proportion of participants with hospital readmission or an emergency department visit following discharge from the index antepartum hospitalization and prior to delivery.
From discharge from the index hospitalization through delivery, up to approximately 6 months after enrollment.
Birth Weight
時間枠:At delivery, up to approximately 6 months after enrollment.
Neonatal birth weight in grams, collected from the medical record and compared between the intervention and control groups.
At delivery, up to approximately 6 months after enrollment.
Apgar Score at 1 Minute
時間枠:At delivery.
Apgar score at 1 minute after birth, ranging from 0 to 10, with higher scores indicating better neonatal condition.
At delivery.
Apgar Score at 5 Minutes
時間枠:At delivery.
Apgar score at 5 minutes after birth, ranging from 0 to 10, with higher scores indicating better neonatal condition.
At delivery.
Umbilical Arterial Cord Blood pH
時間枠:At delivery.
Umbilical arterial cord blood pH measured at delivery and collected from the medical record.
At delivery.
Umbilical Venous Cord Blood pH
時間枠:At delivery.
Umbilical venous cord blood pH measured at delivery and collected from the medical record.
At delivery.
Umbilical Arterial and Venous Cord Blood Base Excess
時間枠:At delivery.
Umbilical arterial and Venous cord blood base excess measured at delivery and collected from the medical record.
At delivery.
Neonatal Intensive Care Unit Admission
時間枠:From birth through neonatal hospital discharge, assessed up to 6 months after birth.
Proportion of newborns admitted to the neonatal intensive care unit (NICU), collected from the medical record and compared between the intervention and control groups.
From birth through neonatal hospital discharge, assessed up to 6 months after birth.
Postpartum Endometritis
時間枠:From delivery through 6 weeks postpartum.
Proportion of participants diagnosed with postpartum endometritis, collected from the medical record and compared between the intervention and control groups.
From delivery through 6 weeks postpartum.
Postpartum Hemorrhage
時間枠:From delivery through postpartum hospital discharge, assessed up to 6 weeks postpartum.
Proportion of participants experiencing postpartum hemorrhage, defined as estimated blood loss greater than 1000 mL, collected from the medical record and compared between the intervention and control groups.
From delivery through postpartum hospital discharge, assessed up to 6 weeks postpartum.
Length of Postpartum Hospitalization
時間枠:From delivery through postpartum hospital discharge, assessed up to 6 weeks postpartum.
Duration of postpartum hospitalization in days, collected from the medical record and compared between the intervention and control groups.
From delivery through postpartum hospital discharge, assessed up to 6 weeks postpartum.
Postpartum Readmission or Emergency Department Visit
時間枠:From postpartum hospital discharge through 6 weeks postpartum.
Proportion of participants with hospital readmission or an emergency department visit during the postpartum period.
From postpartum hospital discharge through 6 weeks postpartum.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2028年1月1日

研究の完了 (推定)

2028年7月23日

試験登録日

最初に提出

2026年5月15日

QC基準を満たした最初の提出物

2026年9月12日

最初の投稿 (実際)

2026年9月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月16日

QC基準を満たした最後の更新が送信されました

2026年9月12日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

This study is planned as a single-center trial, and at this stage, there are no plans or agreements in place for sharing individual participant data (IPD). Future considerations for data-sharing agreements may be evaluated based on future research collaborations and institutional policies.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する